This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

A Hep C Breakdown Will Test Investors' Love For Vertex Pharma

CAMBRIDGE, Mass. ( TheStreet) -- We're about to test the thesis that investors are only interested in Vertex Pharmaceuticals (VRTX - Get Report) for its blockbuster cystic fibrosis drug program and care little for anything the company does in hepatitis C.

After Thursday's close, Vertex announced a U.S. Food and Drug Administration partial clinical hold on its lead hepatitis C drug candidate VX-135 due to liver toxicity seen in patients treated at higher doses.

VX-135 is Vertex's nucleotide "nuc" polymerase inhibitor which is playing catch-up to other more advanced nucs in development for the treatment of hepatitis C, most notably Gilead Sciences' (GILD - Get Report) sofosbuvir.

Either by luck, smarts or a combination of both, Gilead has managed to avoid liver toxicity issues with its nuc (obtained from Pharmasset in the famous $11 billion acquisition at the end of 2012) that have dogged other companies. Today, it's Vertex in trouble, but Idenix Pharmaceuticals (IDIX) and most famously, Bristol-Myers Squibb (BMY - Get Report), have also landed in hot water.

"God really loves Gilead," quipped ISI Group analyst Mark Schoenebaum, in an email to investor clients following the Vertex announcement.

Vertex shares are down 10 percent to $78.77 on news of the VX-135 partial clinical hold, suggesting that, indeed, investors were hoping the company might resurrect its hepatitis C drug business. Today's unfortunate casts a cloud over that idea.

Of course, most of Vertex's $19 billion valuation is centered on the cystic fibrosis drug program, and rightly so.

Gilead shares are up 5 percent to $63.98 in after-hours trading on the Vertex setback plus a strong second-quarter earnings report.

The FDA placed a partial clinical hold on VX-135 because of elevated liver enzymes reported in patients treated with a 400 mg dose of the drug in a phase II study conducted in Europe. These patients stopped taking VX-135 and their liver enzymes returned to normal, the company said.

FDA reacted by barring Vertex from treating any new patients with doses of VX-135 higher than 200 mg in the U.S. Studies involving 100 mg doses of VX-135 continue, the company said.

Hepatitis C studies involving 100 mg and 200 mg doses of VX-135 in Europe are also continuing.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
IDIX $24.50 0.20%
BMY $60.61 0.00%
GILD $107.78 0.00%
VRTX $134.05 0.00%
AAPL $113.29 0.00%

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs